Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AMRN
- CUSIP: N/A
- Web: www.amarincorp.com
- Market Cap: $890.91 million
- Outstanding Shares: 270,792,000
- 50 Day Moving Avg: $3.25
- 200 Day Moving Avg: $3.30
- 52 Week Range: $2.64 - $4.47
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 329.00
- P/E Growth: -1.71
- Annual Revenue: $151.31 million
- Price / Sales: 5.89
- Book Value: ($0.23) per share
- Price / Book: -14.30
- EBIDTA: ($57,340,000.00)
- Net Margins: -51.42%
- Return on Assets: -39.14%
- Debt-to-Equity Ratio: -1.71%
- Current Ratio: 1.74%
- Quick Ratio: 1.46%
- Average Volume: 2.67 million shs.
- Beta: 0.68
- Short Ratio: 2.62
Frequently Asked Questions for Amarin Corporation PLC (NASDAQ:AMRN)
What is Amarin Corporation PLC's stock symbol?
Amarin Corporation PLC trades on the NASDAQ under the ticker symbol "AMRN."
How were Amarin Corporation PLC's earnings last quarter?
Amarin Corporation PLC (NASDAQ:AMRN) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.05) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The company earned $44.95 million during the quarter, compared to analysts' expectations of $40.35 million. The company's revenue for the quarter was up 37.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.07) earnings per share. View Amarin Corporation PLC's Earnings History.
When will Amarin Corporation PLC make its next earnings announcement?
Where is Amarin Corporation PLC's stock going? Where will Amarin Corporation PLC's stock price be in 2017?
4 analysts have issued 1 year price targets for Amarin Corporation PLC's shares. Their predictions range from $5.00 to $10.00. On average, they expect Amarin Corporation PLC's share price to reach $8.00 in the next year. View Analyst Ratings for Amarin Corporation PLC.
What are analysts saying about Amarin Corporation PLC stock?
Here are some recent quotes from research analysts about Amarin Corporation PLC stock:
- 1. Cantor Fitzgerald analysts commented, "At ESC, Novartis released data from its Phase 3 CANTOS study for ACZ885." (8/29/2017)
- 2. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (8/7/2017)
Who are some of Amarin Corporation PLC's key competitors?
Some companies that are related to Amarin Corporation PLC include Insmed (INSM), Intercept Pharmaceuticals (ICPT), Acceleron Pharma (XLRN), Radius Health (RDUS), MyoKardia (MYOK), Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER), Epizyme (EPZM), Five Prime Therapeutics (FPRX) and Athenex (ATNX).
Who are Amarin Corporation PLC's key executives?
Amarin Corporation PLC's management team includes the folowing people:
- Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board
- John F. Thero CPA, President, Chief Executive Officer, Assistant Secretary, Director
- Michael Wayne Kalb CPA, Chief Financial Officer, Senior Vice President
- Stephen B. Ketchum Ph.D., President - Research and Development, Senior Vice President, Chief Scientific Officer
- Joseph T. Kennedy J.D., Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
- Aaron D. Berg, Senior Vice President - Marketing and Sales
- Michael J. Farrell, Vice President - Finance (principal accounting officer and principal financial officer)
- Craig B. Granowitz M.D., Ph.D., Chief Medical Officer
- Joseph S. Zakrzewski, Director
- Patrick J. O'Sullivan, Non-Executive Independent Director
Who owns Amarin Corporation PLC stock?
Amarin Corporation PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Balyasny Asset Management LLC (1.06%), Broadfin Capital LLC (0.94%), FMR LLC (0.75%), Farallon Capital Management LLC (0.55%), California Public Employees Retirement System (0.17%) and Healthcare Value Capital LLC (0.17%). Company insiders that own Amarin Corporation PLC stock include John F Thero and Joseph T Kennedy. View Institutional Ownership Trends for Amarin Corporation PLC.
Who sold Amarin Corporation PLC stock? Who is selling Amarin Corporation PLC stock?
Amarin Corporation PLC's stock was sold by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Broadfin Capital LLC, California Public Employees Retirement System, Ameriprise Financial Inc., Northern Trust Corp, ProShare Advisors LLC, Sterling Capital Management LLC and Private Advisor Group LLC. View Insider Buying and Selling for Amarin Corporation PLC.
Who bought Amarin Corporation PLC stock? Who is buying Amarin Corporation PLC stock?
Amarin Corporation PLC's stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., GSA Capital Partners LLP, Intrinsic Edge Capital Management LLC, Stonepine Capital Management LLC, OxFORD Asset Management LLP, Airain ltd, Dynamic Technology Lab Private Ltd and Perkins Capital Management Inc.. View Insider Buying and Selling for Amarin Corporation PLC.
How do I buy Amarin Corporation PLC stock?
Shares of Amarin Corporation PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amarin Corporation PLC's stock price today?
MarketBeat Community Rating for Amarin Corporation PLC (NASDAQ AMRN)MarketBeat's community ratings are surveys of what our community members think about Amarin Corporation PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Amarin Corporation PLC stock can currently be purchased for approximately $3.29.
Earnings History for Amarin Corporation PLC (NASDAQ:AMRN)Earnings History by Quarter for Amarin Corporation PLC (NASDAQ AMRN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017|| || || || || || || || |
|8/2/2017||6/30/2017||($0.06)||($0.05)||$40.35 million||$44.95 million||View||Listen|
|5/4/2017||3/31/2017||($0.07)||($0.08)||$37.85 million||$34.60 million||View||Listen|
|2/28/2017||12/31/2016||($0.09)||($0.05)||$36.13 million||$38.40 million||View||Listen|
|11/3/2016||Q316||($0.10)||($0.08)||$32.03 million||$32.40 million||View||N/A|
|8/4/2016||Q216||($0.13)||($0.07)||$29.97 million||$32.82 million||View||N/A|
|5/5/2016||Q116||($0.11)||($0.14)||$26.77 million||$25.30 million||View||N/A|
|2/25/2016||Q415||($0.08)||($0.12)||$23.62 million||$26.40 million||View||Listen|
|11/4/2015||Q315||($0.12)||($0.18)||$21.93 million||$21.30 million||View||N/A|
|8/6/2015||Q2||($0.12)||($0.15)||$19.10 million||$17.70 million||View||N/A|
|5/8/2015||Q115||($0.11)||($0.18)||$21.86 million||$15.60 million||View||N/A|
|3/3/2015||Q414||($0.13)||($0.11)||$17.40 million||$16.50 million||View||N/A|
|11/6/2014||Q314||($0.14)||($0.18)||$14.87 million||$14.15 million||View||N/A|
|8/7/2014||Q214||($0.15)||($0.14)||$12.86 million||$12.60 million||View||N/A|
|5/9/2014||Q114||($0.18)||($0.17)||$11.65 million||$11.00 million||View||N/A|
|2/27/2014||Q413||($0.23)||($0.26)||$11.17 million||$10.10 million||View||N/A|
|11/7/2013||($0.32)||($0.25)||$10.25 million||$8.40 million||View||N/A|
|8/8/2013||Q2 2013||($0.38)||($0.26)||$5.50 million||View||N/A|
|5/9/2013||Q1 2013||($0.39)||($0.41)||$5.21 million||$2.34 million||View||N/A|
Earnings Estimates for Amarin Corporation PLC (NASDAQ:AMRN)
2017 EPS Consensus Estimate: ($0.23)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Amarin Corporation PLC (NASDAQ:AMRN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Amarin Corporation PLC (NASDAQ:AMRN)
Insider Ownership Percentage: 3.72%Insider Trades by Quarter for Amarin Corporation PLC (NASDAQ:AMRN)
Institutional Ownership Percentage: 37.76%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/3/2017||Joseph T. Kennedy||General Counsel||Sell||307,911||$4.00||$1,231,644.00|| |
|2/1/2016||John F Thero||CEO||Buy||25,000||$1.37||$34,250.00|| |
|8/11/2015||John F Thero||CEO||Buy||20,000||$2.35||$47,000.00|| |
|11/12/2014||John F Thero||Insider||Buy||50,000||$0.83||$41,500.00|| |
|11/11/2014||Michael James Farrell||Insider||Buy||5,500||$0.84||$4,620.00|| |
Headline Trends for Amarin Corporation PLC (NASDAQ:AMRN)
Latest Headlines for Amarin Corporation PLC (NASDAQ:AMRN)
Amarin Corporation PLC (AMRN) Chart for Sunday, September, 24, 2017